New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Subscribe To Our Newsletter & Stay Updated
